2nd CRISPR-Based Therapy Analytical Development Summit

Kongressthemen
As CRISPR-based therapies become ever complex, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy, prior to finalizing guidance on genome editing therapies in January.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2433843-3?pid=4832

Speakers: Andrew Kernytsky, Principal Consultant, Next Gen Editing, Bryant Chia, Scientist, Analytical Chemistry and Structural Biology, Editas Medicine, and more

https://go.evvnt.com/2433843-2?pid=4832

Frau Jasmine Fletcher